BIONEXUS GENE LAB CORP (BGLC)
US0906282076 - Common Stock
We assign a fundamental rating of 3 out of 10 to BGLC. BGLC was compared to 48 industry peers in the Trading Companies & Distributors industry. BGLC has a great financial health rating, but its profitability evaluates not so good. BGLC does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
BGLC had negative earnings in the past year.
In the past year BGLC has reported a negative cash flow from operations.
In multiple years BGLC reported negative net income over the last 5 years.
In multiple years BGLC reported negative operating cash flow during the last 5 years.
1.2 Ratios
BGLC's Return On Assets of -19.80% is on the low side compared to the rest of the industry. BGLC is outperformed by 95.83% of its industry peers.
Looking at the Return On Equity, with a value of -23.10%, BGLC is doing worse than 91.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.8% | ||
| ROE | -23.1% | ||
| ROIC | N/A |
ROA(3y)-6.45%
ROA(5y)-5.78%
ROE(3y)-7.39%
ROE(5y)-5.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BGLC has a Gross Margin of 13.88%. This is amonst the worse of the industry: BGLC underperforms 95.83% of its industry peers.
In the last couple of years the Gross Margin of BGLC has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BGLC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 13.88% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-0.97%
2. Health
2.1 Basic Checks
BGLC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BGLC has more shares outstanding
Compared to 5 years ago, BGLC has more shares outstanding
BGLC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
BGLC has an Altman-Z score of 2.76. This is not the best score and indicates that BGLC is in the grey zone with still only limited risk for bankruptcy at the moment.
BGLC has a Altman-Z score (2.76) which is in line with its industry peers.
BGLC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.76 |
ROIC/WACCN/A
WACC10.67%
2.3 Liquidity
A Current Ratio of 5.60 indicates that BGLC has no problem at all paying its short term obligations.
BGLC's Current ratio of 5.60 is amongst the best of the industry. BGLC outperforms 100.00% of its industry peers.
A Quick Ratio of 4.87 indicates that BGLC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.87, BGLC belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.6 | ||
| Quick Ratio | 4.87 |
3. Growth
3.1 Past
BGLC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -177.05%.
The Revenue for BGLC has decreased by -11.44% in the past year. This is quite bad
The Revenue has been growing by 115.55% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-177.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.35%
Revenue 1Y (TTM)-11.44%
Revenue growth 3Y-4.98%
Revenue growth 5Y115.55%
Sales Q2Q%-23.17%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
BGLC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for BGLC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIONEXUS GENE LAB CORP
NASDAQ:BGLC (12/4/2024, 8:00:01 PM)
After market: 0.31 -0.01 (-3.43%)0.321
+0.01 (+4.59%)
Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryTrading Companies & Distributors
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.77M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.8% | ||
| ROE | -23.1% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 13.88% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.6 | ||
| Quick Ratio | 4.87 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-177.05%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-11.44%
Revenue growth 3Y-4.98%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y